A non-steroidal selective androgen receptor modulator (SARM) developed by Radius Health, now with Ellipses Pharma as vosilasarm. The published human harm evidence — four DILI case reports plus a myocarditis case and a gynecomastia / HPTA case — outweighs the published human benefit evidence (one Phase 1 partial response in 22 patients).
RAD-140 has more peer-reviewed published human harm evidence than published human benefit evidence. This is rare and load-bearing for any decision to use it.
On the harm side: the Phase 1 trial in metastatic breast cancer (LoRusso 2022, PMID 34565686, n=22) showed AST elevations in 59.1%, ALT in 45.5%, and hyperbilirubinemia in 27.3% of patients at MTD 100 mg/day, with one partial response. Outside the trial, four peer-reviewed DILI case reports document severe cholestatic or mixed-pattern liver injury from gray-market bodybuilding use: Leung 2022 (PMID 36561105), Mohamed 2023 (PMID 36945289), Perananthan 2024 (PMID 38444893), and Demangone 2024 (PMID 39328701). Add Padappayil 2022 (PMID 35233331) for acute myocarditis and Chong 2024 (PMID 39145153) for gynecomastia and HPTA suppression from a SARM-containing supplement. NIH LiverTox has a dedicated SARM monograph (NBK619971).
On the benefit side: one partial response in 22 cancer patients in a Phase 1 trial. That's it. If you decide to use RAD-140 anyway, do so with the harm asymmetry fully visible.
RAD-140 (testolone, clinical name vosilasarm) is a non-steroidal small-molecule selective androgen receptor modulator (SARM). It's not a peptide despite living in peptide-adjacent vendor catalogs — it's a small molecule.
Provenance is well-documented. RAD-140 was discovered and characterized at Radius Health, Inc. (Cambridge, MA), with original characterization by Miller et al. ACS Med Chem Lett 2010 (PMID 24900290). The clinical program was later licensed to Ellipses Pharma (London) under the development name vosilasarm. The first-in-human trial (NCT03088527) ran in postmenopausal women with ER+/HER2− metastatic breast cancer — sponsored by Stemline Therapeutics during a transitional phase, completed 2020, published as LoRusso 2022 (PMID 34565686). This isn't a "Chinese research chemical with no IP trail" compound. The published trial just doesn't support most of what gray-market vendors claim.
RAD-140 binds the androgen receptor with high affinity — sub-nanomolar to low-nanomolar Ki in vitro (Miller 2010 PMID 24900290; Yu 2017 PMID 28974548). The tissue selectivity ("SARM") claim comes from rat preclinical work where RAD-140 produced anabolic effects on levator ani muscle and bone with markedly weaker stimulation of prostate and seminal vesicle weight vs testosterone — the canonical anabolic-vs-androgenic dissociation. Critically, this selectivity does not extend to liver: SARMs as a class produce hepatic injury at gray-market human doses despite their muscle-vs-prostate selectivity.
The breast-cancer mechanism is different. In AR+/ER+ breast-cancer cells, RAD-140 occupancy of AR suppresses ESR1 (estrogen receptor) expression and downstream estrogen-driven proliferation — a fundamentally different mechanism from antiestrogens or aromatase inhibitors (Wei 2023 Cancer Res, PMID 36469363). RAD-140 has also been shown to reduce neuronal cell death from apoptotic insults in cultured hippocampal neurons and protect hippocampal neurons against systemic kainate excitotoxicity in male rats, dependent on MAPK/ERK signaling (Jayaraman 2014, PMID 24428527).
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeThe one Phase 1 trial: LoRusso et al. Clin Breast Cancer 2022 (PMID 34565686), titled "A First-in-Human Phase 1 Study of a Novel Selective Androgen Receptor Modulator (SARM), RAD140, in ER+/HER2− Metastatic Breast Cancer." 22 postmenopausal women with hormone-receptor-positive metastatic breast cancer; dose-escalation; MTD 100 mg/day with dose-limiting toxicity at 150 mg; verified human half-life 44.7 hr (the "16–20 hr" figure that circulates on vendor pages is unanchored); one partial response; hepatic AEs dominant — AST 59.1%, ALT 45.5%, hyperbilirubinemia 27.3%.
The case-report literature now sits in mainstream hepatology. Severe cholestatic and mixed-pattern drug-induced liver injury reports show onset typically 4–12 weeks into use, bilirubin peaks in the 10–30 mg/dL range, recovery taking months. Some cases require liver biopsy and prolonged corticosteroid therapy.
Preclinical reproducibility is genuine. Anabolic muscle and bone effects with relative prostate sparing are robust across the preclinical record (Miller 2010; Puskas 2025 PMID 40680216). Neuroprotection is reproducible (Jayaraman 2014). Negative effects on female-mouse muscle adaptation, frailty status, and mortality have been reported (Brown 2023 PMID 37758180) — the "anabolic" framing isn't symmetric across sex or age.
StackTrax doesn't endorse RAD-140 use. The dosing below is community / forum convention. The hepatotoxicity case reports involved gray-market users at typical "cycle" doses, not high-dose outliers.
| Parameter | Community-cited Range |
|---|---|
| Dose | 5–30 mg/day oral |
| Cycle length | 4–8 weeks (community); the Phase 1 oncology trial dosed continuously up to 100 mg/day |
| Route | Oral (capsule or liquid) |
| Half-life | 44.7 hr (verified human, LoRusso 2022) — supports once-daily dosing |
If used: get a baseline liver panel (AST, ALT, ALP, bilirubin, GGT) before starting; repeat at 2 weeks, 4 weeks, then monthly. Stop immediately if any liver enzyme exceeds 3× ULN, or if any symptom of jaundice, dark urine, or scleral icterus appears. Get baseline lipid panel (SARMs lower HDL as a class) and baseline testosterone, LH, FSH (class effect of HPTA suppression). Have a hepatologist's number ready — not a peptide-clinic Telegram contact.
Pre-filled with a typical RAD-140 (Testolone) setup. Edit any field — the draw updates live.
Insulin syringe — 100 units = 1 mL
Free account. Saves your reconstitution + schedules doses + tracks every vial.
Dosing cheat sheet, reconstitution reference, and cycle planning — delivered to your inbox.
Hepatotoxicity is dominant. Cholestatic and mixed-pattern drug-induced liver injury. AST/ALT elevations in over 50% of trial patients at 100 mg/day. Multiple peer-reviewed case reports of severe DILI from gray-market doses (5–30 mg/day range). Onset typically 4–12 weeks; recovery weeks to months; some cases require corticosteroids.
HPTA suppression is a class effect. SARMs as a class suppress LH/FSH and endogenous testosterone. Chong 2024 (PMID 39145153) demonstrates reversible gynecomastia and hypogonadism. Recovery time varies; PCT regimens used by gray-market users are not validated in trials.
Cardiac signal. Padappayil 2022 (PMID 35233331) reports acute myocarditis. The FDA SARM warning explicitly cites heart attack and stroke risk. Brown 2023 (PMID 37758180) reported negative impacts on skeletal muscle adaptation, frailty status, and mortality risk in female mice — the anabolic framing isn't symmetric across sex or age.
Lipid changes. Class effect — SARMs lower HDL. The specific RAD-140 lipid signature isn't characterized in published human work beyond the Phase 1 record.
Other community reports: sleep disruption and insomnia, mood changes (irritability, aggression), headaches.
Anabolic-androgenic steroids (AAS). Different chemistry (small-molecule SARM vs steroid scaffold). Both are AR agonists; both produce HPTA suppression. SARMs were marketed as "safer" alternatives, but the published case-report record doesn't support that framing for RAD-140.
Other SARMs: LGD-4033 (ligandrol), MK-2866 (ostarine), S-23, RAD-150 (TLB-150). Each has its own preclinical and mostly limited clinical record. The DILI signal is a class concern.
Testosterone replacement therapy (TRT). A regulated medical therapy with established monitoring protocols. RAD-140 is a research chemical without medical supervision.
Vosilasarm. The clinical-development name for RAD-140 under Ellipses Pharma. Same molecule.
RAD-140 (Testolone) is a research peptide not approved by the FDA for human use. It is sold only as a research chemical, and StackTrax does not endorse or facilitate personal use.
Quality varies enormously among research-chemical suppliers. At minimum, look for:
StackTrax’s preferred partner NextGen Peptides does not currently carry RAD-140 (Testolone)in their catalog, which is why you don’t see a direct purchase link here. Other major research-chemical suppliers carry it; we don’t specifically recommend one for this compound.
Build your protocol, log every dose, monitor your body's response, and get reminders so you never miss a dose.
Start Tracking FreeNo. RAD-140 (testolone, clinical name vosilasarm) is not approved by the FDA for any indication. The FDA has issued public consumer warnings about SARMs and multiple enforcement letters. It is sold gray-market with research-chemical labeling. WADA prohibits it at all times under S1.2 (Other Anabolic Agents) and names it explicitly.
Community ranges are 5 to 30 mg/day oral, typically run as 4 to 8 week cycles. The verified human half-life is 44.7 hours (LoRusso 2022), which supports once-daily dosing. The Phase 1 oncology trial dosed continuously up to 100 mg/day with dose-limiting toxicity at 150 mg. None of the community-cycle numbers come from a human dose-finding trial.
No. RAD-140 is a non-steroidal small-molecule SARM (selective androgen receptor modulator), not a steroid. Both AAS and SARMs are androgen receptor agonists and both produce HPTA suppression, but RAD-140 is a different chemical scaffold. SARMs were originally marketed as safer alternatives to anabolic steroids — the published case-report record does not support that framing for RAD-140 specifically.
RAD-140 produces cholestatic and mixed-pattern drug-induced liver injury. In the Phase 1 trial at 100 mg/day, AST was elevated in 59.1% of patients, ALT in 45.5%, and bilirubin in 27.3%. Outside the trial, four peer-reviewed DILI case reports (Leung 2022, Mohamed 2023, Perananthan 2024, Demangone 2024) document severe liver injury from gray-market bodybuilding use at 5 to 30 mg/day. Onset is typically 4 to 12 weeks; bilirubin can peak at 10 to 30 mg/dL; recovery takes months and some cases require corticosteroids. NIH LiverTox has a dedicated SARM monograph (NBK619971).
Testosterone replacement therapy is a regulated medical treatment with established monitoring protocols, lab panels, and physician oversight. RAD-140 is an unapproved research chemical with no medical supervision pathway, no validated PCT, and a documented hepatotoxicity signal not seen with TRT. The preclinical "tissue selectivity" framing (anabolic on muscle and bone, weaker on prostate) does not extend to liver — SARMs as a class produce hepatic injury at gray-market doses despite muscle-vs-prostate selectivity.
Yes. RAD-140 is prohibited at all times under WADA S1.2 (Other Anabolic Agents, SARMs) and is named explicitly on the 2026 Prohibited List. Detection windows are extended, and metabolite-ratio analysis can fingerprint dosing pattern (Wagener 2022, PMID 35888790). Athletes subject to anti-doping testing should not use it.
Yes. HPTA suppression is a class effect of SARMs — endogenous testosterone, LH, and FSH are suppressed. Chong 2024 (PMID 39145153) documented reversible gynecomastia and hypogonadism from a SARM-containing supplement. PCT regimens used by gray-market users are not validated in any clinical trial, and recovery time varies between individuals.
Disclaimer: This guide is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. The compounds discussed are not FDA approved for human use. Always consult a qualified healthcare provider before starting any new supplement or peptide protocol. StackTrax does not sell peptides or supplements directly — purchase links go to third-party vendors. StackTrax is not responsible for the products, quality, or business practices of any third-party vendor. This page contains affiliate links — StackTrax may earn a commission on purchases at no extra cost to you.
© 2026 StackTrax, LLC. All rights reserved.
Privacy · Terms · Do Not Sell or Share My Personal Information
StackTrax guides cover peptides and compounds that are not FDA-approved for the uses discussed. The dosing, reconstitution, and safety information is compiled from published research and community protocols for educational purposes only.
Before using any compound mentioned here, consult a qualified healthcare provider. StackTrax does not sell, prescribe, or recommend these substances for personal use.
These pages also contain affiliate links. We may earn a commission on purchases at no extra cost to you — this never changes our editorial recommendations.